Evidence map›Paper›PMID 38356293›Full record

ArticleJournal of pediatric gastroenterology and nutrition2024

Humoral immune response and safety of SARS-CoV-2 vaccination in very early onset inflammatory bowel disease.

Arthur J Kastl, Kimberly N Weaver, Xian Zhang, Jennifer A Strople, Jeremy Adler, Judith R Kelsen, Marla C Dubinsky, Athos Bousvaros, Runa Watkins, Colin Dai and 13 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pediatric gastroenterology and nutrition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 10 institutions in 1 country.

Arthur J KastlDivision of Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Kimberly N WeaverDepartment of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Xian ZhangDepartment of Pediatrics, Division of Pediatric Gastroenterology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Jennifer A StropleAnn & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
Jeremy AdlerSusan B. Meister Child Health Evaluation and Research Center and Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA.
Judith R KelsenDivision of Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Marla C DubinskyDepartment of Pediatrics, Susan and Leonard Feinstein IBD Center, Icahn School of Medicine, Mount Sinai, New York, USA.
Athos BousvarosChildren's Hospital, Boston, Massachusetts, USA.
Runa WatkinsDivision of Pediatric Gastroenterology and Nutrition, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Colin DaiDepartment of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Raymond K CrossDivision of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Peter D R HigginsDepartment of Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
Ryan UngaroDepartment of Medicine, Susan and Leonard Feinstein IBD Center, Icahn School of Medicine, Mount Sinai, New York, USA.
Meenakshi BewtraDepartment of Medicine, Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Emanuelle A BellaguardaDivision of Gastroenterology and Hepatology, Northwestern University, Chicago, Illinois, USA.
Francis A FarrayeDivision of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.
Kelly ChunEsoterix Specialty Laboratory, LabCorp, Calabasas, California, USA.
Michael ZikryEsoterix Specialty Laboratory, LabCorp, Calabasas, California, USA.
Monique BastidasEsoterix Specialty Laboratory, LabCorp, Calabasas, California, USA.
Margie E BoccieriDepartment of Pediatrics, Division of Pediatric Gastroenterology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Ann FirestineDepartment of Pediatrics, Division of Pediatric Gastroenterology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Millie D LongDepartment of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Michael D KappelmanDepartment of Pediatrics, Division of Pediatric Gastroenterology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
University of North Carolina at Chapel Hill · USLabCorp (United States) · USChildren's Hospital of Philadelphia · USUniversity of Maryland, Baltimore · USUniversity of Michigan–Ann Arbor · USBoston Children's Hospital · USLurie Children's Hospital · USMayo Clinic in Florida · USNorthwestern University · USUniversity of Pennsylvania · US

Funding

Integration of genomics and transcriptomics to investigate biological pathways in very early onset IBDR01DK127044 · NIDDK · CHILDREN'S HOSP OF PHILADELPHIA · PI KELSEN, JUDITH RACHEL · 2021 to 2025
$3.4M
Assessing Predictors of Response to Anti-Tumor Necrosis Alpha Therapy in Early Crohns DiseaseK23DK111995 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI UNGARO, RYAN · 2019 to 2023
$948k
An integrative approach to understanding the genetic basis of very early onset inflammatory bowel diseaseR01DK111843 · NIDDK · CHILDREN'S HOSP OF PHILADELPHIA · PI KELSEN, JUDITH RACHEL · 2018 to 2020
$772k
NIDDK NIH HHS K23 DK111995NIDDK NIH HHS R01 DK111843NIDDK NIH HHS R01 DK127044
6 · The paper itself

Abstract

Children with very early onset inflammatory bowel disease (VEO-IBD) may respond differently to coronavirus disease 2019 (COVID-19) immunization compared to healthy children or other patients with IBD. We recruited children with VEO-IBD <6 years of age and younger following receipt of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. Demographics, IBD characteristics, medication use, adverse events (AEs) and IBD exacerbations were collected. Blood draws (optional) were obtained for measurement of antireceptor binding domain (RBD) IgG antibodies following vaccination. Of 41 participants, none required emergency department visit or hospitalization due to AE, and only one experienced IBD exacerbation. Detectable antibody was present in 19/19 participants who provided blood sample; 6/7 participants (86%) had durable humoral response 12 months postvaccination. Children with VEO-IBD experience robust humoral immune response to COVID-19 immunization. Severe AEs were rare. These findings provide reassurance that children with VEO-IBD respond well and safely to SARS-CoV-2 vaccination.

Indexed as

COVID-19Inflammatory Bowel DiseasesAntibodies, ViralChildCOVID-19 VaccinesHumansImmunity, HumoralImmunoglobulin GSARS-CoV-2VaccinationAntibodies, ViralCOVID-19 VaccinesImmunoglobulin GantibodyCOVID‐19ModernaPfizervaccine

Identifiers

PMID38356293
PMCPMC12002066
OpenAlexW4391841580

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.